Torrent Pharmaceuticals launches its biosimilar Adalimumab in India

13 Jan 2016 Evaluate

Torrent Pharmaceuticals has launched its biosimilar Adalimumab in India, used for the treatment of auto immune disorders, under the brand name ‘Adfrar’. The company’s product will be available as pre-filled syringe of 40 mg.

Adalimumab is a preferred therapy for the treatment of auto immune disorders and has wide applications for treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis and plaque psoriasis among others.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Torrent Pharma Share Price

3826.15 -15.55 (-0.40%)
01-Jan-2026 09:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1711.05
Dr. Reddys Lab 1253.70
Cipla 1502.90
Zydus Lifesciences 909.80
Lupin 2088.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×